Sfoglia per Autore
Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma
2013-01-01 Gay F.; Mina R.; Troia R.; Bringhen S.
Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma
2014-01-01 Bringhen S.; Gay F.; Donato F.; Troia R.; Mina R.; Palumbo A.
Monoclonal antibodies currently in Phase II and III trials for multiple myeloma
2014-01-01 Donato F.; Gay F.; Bringhen S.; Troia R.; Palumbo A.
Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: A pooled analysis
2017-01-01 Gay F, Oliva S, Petrucci MT, Montefusco V, Conticello C, Musto P, Catalano L, Evangelista A, Spada S, Campbell P, Ria R, Salvini M, Offidani M, Carella AM, Omedé P, Liberati AM, Troia R, Cafro AM, Malfitano A, Falcone AP, Caravita T, Patriarca F, Nagler A, Spencer A, Hajek R, Palumbo A, Boccadoro M.
Melphalan hydrochloride for the treatment of multiple myeloma
2017-01-01 Esma, Fabrizio; Salvini, Marco; Troia, Rossella; Boccadoro, Mario; Larocca, Alessandra; Pautasso, Chiara*
Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma
2017-01-01 Offidani, Massimo; Corvatta, Laura; Bringhen, Sara; Gentili, Silvia; Troia, Rossella; Maracci, Laura; Larocca, Alessandra; Gay, Francesca; Leoni, Pietro; Boccadoro, Mario
Promises and pitfalls in the use of PD-1/PD-L1 inhibitors in multiple myeloma
2018-01-01 Oliva S.; Troia R.; D'Agostino M.; Boccadoro M.; Gay F.
Pharmacokinetic drug evaluation of ixazomib citrate for the treatment of multiple myeloma
2018-01-01 Salvini, Marco; Troia, Rossella; Giudice, Davide; Pautasso, Chiara; Boccadoro, Mario; Larocca, Alessandra*
Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study
2018-01-01 Bringhen S.; Mina R.; Cafro A.M.; Liberati A.M.; Spada S.; Belotti A.; Gaidano G.; Patriarca F.; Troia R.; Fanin R.; De Paoli L.; Rossi G.; Lombardo A.; Bertazzoni P.; Palumbo A.; Sonneveld P.; Boccadoro M.
Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis
2019-01-01 Gambella M.; Omede P.; Spada S.; Muccio V.E.; Gilestro M.; Saraci E.; Grammatico S.; Larocca A.; Conticello C.; Bernardini A.; Gamberi B.; Troia R.; Liberati A.M.; Offidani M.; Rocci A.; Palumbo A.; Cavo M.; Sonneveld P.; Boccadoro M.; Oliva S.
Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study
2020-01-01 Cavo M.; Gay F.; Beksac M.; Pantani L.; Petrucci M.T.; Dimopoulos M.A.; Dozza L.; van der Holt B.; Zweegman S.; Oliva S.; van der Velden V.H.J.; Zamagni E.; Palumbo G.A.; Patriarca F.; Montefusco V.; Galli M.; Maisnar V.; Gamberi B.; Hansson M.; Belotti A.; Pour L.; Ypma P.; Grasso M.; Croockewit A.; Ballanti S.; Offidani M.; Vincelli I.D.; Zambello R.; Liberati A.M.; Andersen N.F.; Broijl A.; Troia R.; Pascarella A.; Benevolo G.; Levin M.-D.; Bos G.; Ludwig H.; Aquino S.; Morelli A.M.; Wu K.L.; Boersma R.; Hajek R.; Durian M.; von dem Borne P.A.; Caravita di Toritto T.; Zander T.; Specchia G.; Waage A.; Gimsing P.; Mellqvist U.-H.; van Marwijk Kooy M.; Minnema M.; Mandigers C.; Cafro A.M.; Palmas A.; Carvalho S.; Spencer A.; Boccadoro M.; Sonneveld P.
Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial
2021-01-01 Oliva, Stefania; Hofste op Bruinink, Davine; Rihova, Lucie; D'Agostino, Mattia; Pantani, Lucia; Capra, Andrea; van der Holt, Bronno; Troia, Rossella; Petrucci, Maria Teresa; Villanova, Tania; Vsianska, Pavla; Jugooa, Romana; Brandt-Hagens, Claudia; Gilestro, Milena; Offidani, Massimo; Ribolla, Rossella; Galli, Monica; Hajek, Roman; Gay, Francesca; Cavo, Michele; Omedé, Paola; van der Velden, Vincent H J; Boccadoro, Mario; Sonneveld, Pieter
A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma
2021-01-01 Oliva S.; De Paoli L.; Ruggeri M.; Caltagirone S.; Troia R.; Oddolo D.; D'Agostino M.; Gilestro M.; Mina R.; Saraci E.; Margiotta Casaluci G.; Genuardi E.; Bringhen S.; Boccadoro M.; Omede P.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma | 2013 | Gay F.; Mina R.; Troia R.; Bringhen S. | |
| Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma | 2014 | Bringhen S.; Gay F.; Donato F.; Troia R.; Mina R.; Palumbo A. | |
| Monoclonal antibodies currently in Phase II and III trials for multiple myeloma | 2014 | Donato F.; Gay F.; Bringhen S.; Troia R.; Palumbo A. | |
| Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: A pooled analysis | 2017 | Gay F, Oliva S, Petrucci MT, Montefusco V, Conticello C, Musto P, Catalano L, Evangelista A, Spada S, Campbell P, Ria R, Salvini M, Offidani M, Carella AM, Omedé P, Liberati AM, Troia R, Cafro AM, Malfitano A, Falcone AP, Caravita T, Patriarca F, Nagler A, Spencer A, Hajek R, Palumbo A, Boccadoro M. | |
| Melphalan hydrochloride for the treatment of multiple myeloma | 2017 | Esma, Fabrizio; Salvini, Marco; Troia, Rossella; Boccadoro, Mario; Larocca, Alessandra; Pautasso, Chiara* | |
| Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma | 2017 | Offidani, Massimo; Corvatta, Laura; Bringhen, Sara; Gentili, Silvia; Troia, Rossella; Maracci, Laura; Larocca, Alessandra; Gay, Francesca; Leoni, Pietro; Boccadoro, Mario | |
| Promises and pitfalls in the use of PD-1/PD-L1 inhibitors in multiple myeloma | 2018 | Oliva S.; Troia R.; D'Agostino M.; Boccadoro M.; Gay F. | |
| Pharmacokinetic drug evaluation of ixazomib citrate for the treatment of multiple myeloma | 2018 | Salvini, Marco; Troia, Rossella; Giudice, Davide; Pautasso, Chiara; Boccadoro, Mario; Larocca, Alessandra* | |
| Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study | 2018 | Bringhen S.; Mina R.; Cafro A.M.; Liberati A.M.; Spada S.; Belotti A.; Gaidano G.; Patriarca F.; Troia R.; Fanin R.; De Paoli L.; Rossi G.; Lombardo A.; Bertazzoni P.; Palumbo A.; Sonneveld P.; Boccadoro M. | |
| Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis | 2019 | Gambella M.; Omede P.; Spada S.; Muccio V.E.; Gilestro M.; Saraci E.; Grammatico S.; Larocca A.; Conticello C.; Bernardini A.; Gamberi B.; Troia R.; Liberati A.M.; Offidani M.; Rocci A.; Palumbo A.; Cavo M.; Sonneveld P.; Boccadoro M.; Oliva S. | |
| Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study | 2020 | Cavo M.; Gay F.; Beksac M.; Pantani L.; Petrucci M.T.; Dimopoulos M.A.; Dozza L.; van der Holt B.; Zweegman S.; Oliva S.; van der Velden V.H.J.; Zamagni E.; Palumbo G.A.; Patriarca F.; Montefusco V.; Galli M.; Maisnar V.; Gamberi B.; Hansson M.; Belotti A.; Pour L.; Ypma P.; Grasso M.; Croockewit A.; Ballanti S.; Offidani M.; Vincelli I.D.; Zambello R.; Liberati A.M.; Andersen N.F.; Broijl A.; Troia R.; Pascarella A.; Benevolo G.; Levin M.-D.; Bos G.; Ludwig H.; Aquino S.; Morelli A.M.; Wu K.L.; Boersma R.; Hajek R.; Durian M.; von dem Borne P.A.; Caravita di Toritto T.; Zander T.; Specchia G.; Waage A.; Gimsing P.; Mellqvist U.-H.; van Marwijk Kooy M.; Minnema M.; Mandigers C.; Cafro A.M.; Palmas A.; Carvalho S.; Spencer A.; Boccadoro M.; Sonneveld P. | |
| Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial | 2021 | Oliva, Stefania; Hofste op Bruinink, Davine; Rihova, Lucie; D'Agostino, Mattia; Pantani, Lucia; Capra, Andrea; van der Holt, Bronno; Troia, Rossella; Petrucci, Maria Teresa; Villanova, Tania; Vsianska, Pavla; Jugooa, Romana; Brandt-Hagens, Claudia; Gilestro, Milena; Offidani, Massimo; Ribolla, Rossella; Galli, Monica; Hajek, Roman; Gay, Francesca; Cavo, Michele; Omedé, Paola; van der Velden, Vincent H J; Boccadoro, Mario; Sonneveld, Pieter | |
| A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma | 2021 | Oliva S.; De Paoli L.; Ruggeri M.; Caltagirone S.; Troia R.; Oddolo D.; D'Agostino M.; Gilestro M.; Mina R.; Saraci E.; Margiotta Casaluci G.; Genuardi E.; Bringhen S.; Boccadoro M.; Omede P. |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile